Dr. Jagannath on the Safety Profile of Selinexor in Multiple Myeloma
Sundar Jagannath, MD, discusses the use and toxicity profile of selinexor in multiple myeloma treatment.
Sundar Jagannath, MD, a professor of medicine, hematology, and medical oncology at The Tisch Cancer Institute, Mount Sinai Hospital, discusses the use and safety profile of selinexor (Xpovio) in multiple myeloma treatment.
Selinexor, a first-in-class novel agent, is used in patients who had failed all other drugs. It was effective in 26% patients and a few patients went into complete remission, achieving minimal residual disease—negative status, explains Jagannath. In addition to the promising results, says Jagannath, selinexor is an orally administered drug, making it easy for patients to take at home.
The safety profile of selinexor shows no organ, cardiac, liver, or renal toxicities and no neuropathy. The drug was administered safely in patients with advanced myeloma who had low platelet count and poor kidney function, according to Jagannath. Significant adverse events (AEs) include nausea, vomiting, and fatigue, all of which affect quality of life for the patient; however, regimens to prevent nausea and vomiting are available to patients who experience those AEs, concludes Jagannath.
